Lv1
40 积分 2025-08-11 加入
Toxicity and response criteria of the Eastern Cooperative Oncology Group
4天前
已完结
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC
20天前
已完结
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
20天前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
21天前
已完结
The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges
27天前
已完结
Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy
1个月前
已完结
Phase I/IIa trial of 18F-prostate specific membrane antigen (PSMA) 1007 PET/CT in healthy volunteers and prostate cancer patients
2个月前
已完结
The FDA Approves PSMA‐targeted Drug for PET Imaging in Men with Prostate Cancer
2个月前
已完结
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
